Solid Organ Transplantation.
Amyloidosis
Cardiomyopathy
Directed-donor
ESRD
Extended-donor
Organ transplantation
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
25
10
2020
pubmed:
26
10
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Please add expansion for AL. Hematologic disease control combined with solid organ transplantation can result in long-term survival in selected patients with light chain (AL) amyloidosis and limited other organ involvement. Restoration of critical cardiac function with organ transplantation can render patients eligible for effective disease-directed therapies, including high-dose therapy and autologous stem cell transplantation. Access to directed-donor organs, exchange programs for renal transplantation, and extended-donor organs for cardiac transplantation improves the availability of organs for patients with AL amyloidosis. Disease recurrence in the graft and progression in other organs remain concerns but often can be managed with a variety of effective plasma cell-directed therapies.
Identifiants
pubmed: 33099431
pii: S0889-8588(20)30101-5
doi: 10.1016/j.hoc.2020.08.006
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1161-1175Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures/conflicts of interests S. Bal: nothing to disclose; H.J. Landau: received research funding and honoraria from Takeda Pharmaceuticals.